# Jianlin Xu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jianlin-xu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,501 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 26 |
| i10-index | 64 |
| Last Known Institution | Kunming Institute of Botany |
| OpenAlex ID | https://openalex.org/A5101798963 |
| ORCID iD | 0000-0002-4380-9067 |
| Works | 142 |

## Researcher papers

- [Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial](https://scholariq.org/papers/combination-of-chemotherapy-and-gefitinib-as-first-line-treatment-for-patients/)
- [Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer](https://scholariq.org/papers/thymidine-kinase-1-combined-with-cea-cyfra21-1-and-nse-improved-its-diagnostic/)
- [Elective versus therapeutic neck dissection in node-negative oral cancer: Evidence from five randomized controlled trials](https://scholariq.org/papers/elective-versus-therapeutic-neck-dissection-in-node-negative-oral-cancer/)
- [Multi-scale integrative analyses identify THBS2<sup>+</sup> cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma](https://scholariq.org/papers/multi-scale-integrative-analyses-identify-thbs2-sup-sup-cancer-associated/)
- [Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma](https://scholariq.org/papers/prognostic-significance-and-adjuvant-chemotherapy-survival-benefits-of-a-solid/)
- [Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy](https://scholariq.org/papers/role-of-anlotinib-induced-ccl2-decrease-in-anti-angiogenesis-and-response/)
- [EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China](https://scholariq.org/papers/egfr-tyrosine-kinase-inhibitor-tki-in-patients-with-advanced-non-small-cell-lung/)
- [Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARβ/δ: a potential therapeutic role for CNS autoimmune disease](https://scholariq.org/papers/inhibition-of-12-15-lipoxygenase-by-baicalein-induces-microglia-ppar-a-potential/)
- [New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer](https://scholariq.org/papers/new-advances-in-antiangiogenic-combination-therapeutic-strategies-for-advanced/)
- [Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies](https://scholariq.org/papers/racial-differences-in-characteristics-and-prognoses-between-asian-and-white/)
- [Characteristics and outcome of small cell lung cancer patients (SCLC) transformed from adenocarcinoma after tyrosine kinase inhibitor treatment](https://scholariq.org/papers/characteristics-and-outcome-of-small-cell-lung-cancer-patients-sclc-transformed/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)

## Researcher university

- [Kunming Institute of Botany](https://scholariq.org/institutions/kunming-institute-of-botany/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.